黑色素瘤
免疫疗法
肿瘤浸润淋巴细胞
肿瘤微环境
癌症研究
免疫系统
医学
转录组
免疫检查点
过继性细胞移植
离体
免疫学
体内
T细胞
生物
基因
基因表达
生物化学
生物技术
作者
Shravan Leonard‐Murali,Chetana Bhaskarla,Ghanshyam Singh Yadav,Sudeep K. Maurya,Chenna R. Galiveti,Joshua A. Tobin,Rachel J. Kann,Eishan Ashwat,Patrick S. Murphy,Anish Bhaswanth Chakka,Vishal Soman,Paul G. Cantalupo,Xinming Zhuo,Gopi Vyas,Dara L. Kozak,Lindsey M. Kelly,Ed Smith,Uma R. Chandran,Yen-Michael Sheng Hsu,Udai S. Kammula
标识
DOI:10.1038/s41467-024-46906-4
摘要
Immune checkpoint inhibition has shown success in treating metastatic cutaneous melanoma but has limited efficacy against metastatic uveal melanoma, a rare variant arising from the immune privileged eye. To better understand this resistance, we comprehensively profile 100 human uveal melanoma metastases using clinicogenomics, transcriptomics, and tumor infiltrating lymphocyte potency assessment. We find that over half of these metastases harbor tumor infiltrating lymphocytes with potent autologous tumor specificity, despite low mutational burden and resistance to prior immunotherapies. However, we observe strikingly low intratumoral T cell receptor clonality within the tumor microenvironment even after prior immunotherapies. To harness these quiescent tumor infiltrating lymphocytes, we develop a transcriptomic biomarker to enable in vivo identification and ex vivo liberation to counter their growth suppression. Finally, we demonstrate that adoptive transfer of these transcriptomically selected tumor infiltrating lymphocytes can promote tumor immunity in patients with metastatic uveal melanoma when other immunotherapies are incapable.
科研通智能强力驱动
Strongly Powered by AbleSci AI